Christopher Keto MD

Board candidate for the American Board of Urology

Cancer treatment

Erectile dysfunction

Female urology

Fertility

General urology

Incontinence

Kidney disorders

Laparoscopic surgery

Pediatric surgery

Prostate enlargement

Robotics

Treatment of kidney stones

Vasectomy

Vasovasostomy

2009 American University of the Caribbean School of Medicine, Coral Gables, FL

Akron General Medical Center

Cleveland Clinic Akron General - Urology

Duke University - Division of Urology (post-doctoral research)

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy; Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ, BJU International, August 2012.

African-American men with low-grade prostate cancer have higher tumor burdens; Tsivian M, Banez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik, TJ, Prostate Cancer and Prostatic Diseases, March 2013.

Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes; Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ, European Urology, March 2014.

Metformin does not affect risk of biochemical recurrence following radical prostatectomy; Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ, Prostate Cancer and Prostatic Diseases, December 2013.

The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort; Gaines AR, Turner EL, Moorman PG, Keto CJ, McPhail ME, Grant DJ, Vidal AC, Hovo C, Cancer Causes Control, August 2014.

American Urological Association